

Glaucoma: a review of adjunctive therapy and new man

Expert Opinion on Pharmacotherapy

8, 3237-3249

DOI: 10.1517/14656566.8.18.3237

Citation Report

#	ARTICLE	IF	CITATIONS
1	Intraocular Pressure Control with Latanoprost/Timolol and Travoprost/Timolol Fixed Combinations. <i>Clinical Drug Investigation</i> , 2008, 28, 767-776.	2.2	9
3	Additive Effect of Brinzolamide on Diurnal Changes in Intraocular Pressure in Latanoprost-treated Eyes. <i>Open Ophthalmology Journal</i> , 2008, 2, 160-164.	0.2	2
4	Primary Open-Angle Glaucoma: Diagnostic Approaches and Management. <i>Journal of the National Medical Association</i> , 2009, 101, 46-50.	0.8	12
5	Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6565-6570.	2.2	61
6	Fixed-Combination Brimonidine/Timolol as Adjunctive Therapy to a Prostaglandin Analog: A 3-Month, Open-Label, Replacement Study in Glaucoma Patients. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2009, 25, 541-544.	1.4	3
8	Timolol Activates the Enzyme Activities of Human Carbonic Anhydrase I and II. <i>Biological and Pharmaceutical Bulletin</i> , 2010, 33, 301-306.	1.4	14
10	Hypotensive action of naturally occurring diterpenes: A therapeutic promise for the treatment of hypertension. <i>FÄ-toterapÄ-Äç</i> , 2010, 81, 690-702.	2.2	60
11	Neuroprotective Effects of C-Type Natriuretic Peptide on Rat Retinal Ganglion Cells. , 2010, 51, 3544.		26
12	Emerging drugs for ocular hypertension. <i>Expert Opinion on Emerging Drugs</i> , 2011, 16, 137-161.	2.4	36
13	Potential for serotonergic agents to treat elevated intraocular pressure and glaucoma: focus on 5-HT ₂ receptor agonists. <i>Expert Review of Ophthalmology</i> , 2011, 6, 105-120.	0.6	6
14	Identification of Novel Competing Î²2AR Phospho-Extracellular Signal Regulated Kinase 1/2 Signaling Pathways in Human Trabecular Meshwork Cells. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2012, 28, 17-25.	1.4	5
15	Latanoprost/timolol fixed combination for the treatment of glaucoma. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1815-1827.	1.8	11
16	Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials. <i>Clinical Ophthalmology</i> , 2014, 8, 643.	1.8	16
17	Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: an overview of reviews. <i>Croatian Medical Journal</i> , 2014, 55, 468-480.	0.7	15
18	AMA0076, a Novel, Locally Acting Rho Kinase Inhibitor, Potently Lowers Intraocular Pressure in New Zealand White Rabbits with Minimal Hyperemia. , 2014, 55, 1006.		78
19	The Diurnal and Nocturnal Effect of Travoprost WithÄSofZia on Intraocular Pressure and Ocular PerfusionÄPressure. <i>American Journal of Ophthalmology</i> , 2014, 157, 44-49.e1.	3.3	8
20	Ophthalmic Imaging and Neuroimaging of the Effects of Glaucoma Treatment. , 2015, , 41-63.		0
21	The role of carbonic anhydrase in the pathogenesis of vascular calcification in humans. <i>Atherosclerosis</i> , 2015, 241, 183-191.	0.8	35

#	ARTICLE	IF	CITATIONS
22	Effect of potassium channel openers in acute and chronic models of glaucoma. <i>Taiwan Journal of Ophthalmology</i> , 2016, 6, 131-135.	0.7	7
23	Evaluation of the effects on choroidal thickness of bimatoprost 0.03% versus a brinzolamide 1.0%/timolol maleate 0.5% fixed combination. <i>Cutaneous and Ocular Toxicology</i> , 2017, 36, 397-403.	1.3	12
24	Effect of monatepil, a calcium channel blocker in ocular hypertensive rabbits. <i>Polish Annals of Medicine</i> , 2017, 24, 171-174.	0.3	1
25	Do We Need to Study Metabolism and Distribution in the Eye: Why, When, and Are We There Yet?. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2276-2281.	3.3	20
26	Hydrus microstent compared to selective laser trabeculoplasty in primary open angle glaucoma: one year results. <i>Clinical and Experimental Ophthalmology</i> , 2017, 45, 120-127.	2.6	66
27	Glaucoma: Biological Trabecular and Neuroretinal Pathology with Perspectives of Therapy Innovation and Preventive Diagnosis. <i>Frontiers in Neuroscience</i> , 2017, 11, 494.	2.8	21
28	Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 1001-1010.	0.9	6
29	Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review (2013-2019). <i>Expert Opinion on Therapeutic Patents</i> , 2019, 29, 805-815.	5.0	21
30	Comparison of clinical effects of two latanoprost 0.005% solutions (Xalatan [®] and Arlatan [®]) in primary open-angle glaucoma or ocular hypertensive patients: a randomized clinical trial. <i>Clinical Ophthalmology</i> , 2019, Volume 13, 679-684.	1.8	1
31	Current and new pharmacotherapeutic approaches for glaucoma. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2027-2040.	1.8	21
32	Persistence and treatment patterns of fixed combination drugs for glaucoma: a retrospective claims database study in Japan. <i>BMC Ophthalmology</i> , 2020, 20, 223.	1.4	5
33	A Comparative Ocular Pharmacokinetics Study of Preservative-Free Latanoprost Unit-Dose Eye Drops and a Benzalkonium Chloride-Preserved Branded Product Following Topical Application to Rabbits. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2020, 36, 522-528.	1.4	9
34	The Hub-and-Spoke Management of Glaucoma. <i>Frontiers in Neuroscience</i> , 2020, 14, 180.	2.8	7
35	Primary Open-Angle Glaucoma Preferred Practice Pattern [®] . <i>Ophthalmology</i> , 2021, 128, P71-P150.	5.2	144
36	Primary Open-Angle Glaucoma Suspect Preferred Practice Pattern [®] . <i>Ophthalmology</i> , 2021, 128, P151-P192.	5.2	26
37	Risk factors leading to trabeculectomy surgery of glaucoma patient using Japanese nationwide administrative claims data: a retrospective non-interventional cohort study. <i>BMC Ophthalmology</i> , 2021, 21, 153.	1.4	5
38	What Is New in Glaucoma: From Treatment to Biological Perspectives. <i>Journal of Ophthalmology</i> , 2021, 2021, 1-10.	1.3	8
39	Medication Adherence and Persistence of Open-Angle Glaucoma Patients in Korea: A Retrospective Study Using National Health Insurance Claims Data. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 4106.	2.6	4

#	ARTICLE	IF	CITATIONS
40	Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment. <i>Current Neuropharmacology</i> , 2017, 15, 637-653.	2.9	21
41	<i>Ophthalmika.</i> , 2008, , 721-743.		0
42	DRUGS IN OPHTHALMOLOGY. , 2009, , 857-861.		0
43	<i>Ophthalmika.</i> , 2009, , 715-737.		0
44	<i>Ophthalmika.</i> , 2010, , 743-767.		0
45	<i>Ophthalmika.</i> , 2011, , 759-784.		0
46	<i>Ophthalmika.</i> , 2012, , 775-801.		0
47	<i>Ophthalmika.</i> , 2013, , 765-792.		0
48	<i>Ophthalmika.</i> , 2014, , 861-890.		0
49	Volumetric and cost evaluation study of glaucoma medical therapy. <i>International Journal of Applied & Basic Medical Research</i> , 2015, 5, 96.	0.5	2
50	<i>Ophthalmika.</i> , 2016, , 621-641.		0
51	<i>Ophthalmika.</i> , 2017, , 641-661.		0
52	<i>Ophthalmika.</i> , 2018, , 693-714.		0
53	<i>Ophthalmika.</i> , 2019, , 877-902.		0
54	<i>Ophthalmika.</i> , 2020, , 733-758.		0
55	<i>Ophthalmika.</i> , 2021, , 639-666.		0
56	In vitro and in vivo evaluation of brimonidine loaded silica nanoparticles-laden silicone contact lenses to manage glaucoma. <i>Journal of Biomaterials Applications</i> , 2022, 37, 333-343.	2.4	3
57	Clinical Practice Management of Primary Open-Angle Glaucoma in the United States: An Analysis of Real-World Evidence. <i>Patient Preference and Adherence</i> , 0, Volume 16, 2213-2227.	1.8	3

#	ARTICLE	IF	CITATIONS
58	Augenerkrankungen. , 2022, , 569-598.		0
59	Carbonic anhydrase inhibitors for the treatment of glaucoma. , 2023, , .		0
60	Additive effects of brimonidine tartrate 0.1%/brinzolamide 1% fixed-dose combination in prostaglandin analog-treated Japanese glaucoma patients. Japanese Journal of Ophthalmology, 0, , .	1.9	0
61	Oxymatrine impedes the progression of endotoxin-induced glaucoma via redox system modulations. Journal of Biochemical and Molecular Toxicology, 2024, 38, .	3.0	0
62	Chemical Insights into Topical Agents in Intraocular Pressure Management: From Glaucoma Etiopathology to Therapeutic Approaches. Pharmaceutics, 2024, 16, 274.	4.5	0